RxDoctor Payments Data

Martin Bress, MD

Cardiovascular Disease · Hollister, CANPI 1720084049

Payments from drug & device makers

$63in general payments, 2019–2025

Across 2 payments — averaging $31.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$50
  • GSK$13

What the payments were for

  • Food & beverage$63100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen1$50
GSK1$13

How this compares

$63 in reported general payments places this provider in the 5th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$371,062
Medicare patients
718
Services billed
8,606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin126$183,223
EliquisApixaban128$172,949
TrulicityDulaglutide57$66,500
XareltoRivaroxaban47$65,905
JanuviaSitagliptin Phosphate25$33,043
EntrestoSacubitril/Valsartan17$19,398
RybelsusSemaglutide15$15,798
Humulin N KwikpenInsulin Nph Human Isophane24$8,704
Atorvastatin Calcium869$7,500
Arnuity ElliptaFluticasone Furoate22$6,636
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$5,769
Humulin NInsulin Nph Human Isophane38$4,938
Metoprolol Succinate375$3,894
DuleraMometasone/Formoterol11$3,620
Tamsulosin Hcl217$3,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArnuity Ellipta$13$6,63622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Hollister

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →